文献速递淋巴瘤

AFM13联合帕博利珠单抗治疗复发或难治性霍奇金淋巴瘤的1b期研究

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
PubMed 文献 · Blood · 2020-01-01

这项1b期剂量递增研究评估了CD30/CD16A双特异性抗体AFM13联合抗PD-1抑制剂帕博利珠单抗在复发或难治性霍奇金淋巴瘤(R/R HL)患者中的安全性和初步疗效,主要终点为最大耐受剂量。联合治疗总体耐受良好,安全性特征与两种药物单药已知特征相似;最高治疗剂量组客观缓解率为88%,总体人群总缓解率为83%;AFM13在联合方案中的半衰期最长可达20.6小时。

要点

  • AFM13联合帕博利珠单抗在重度经治R/R HL中总体耐受良好,安全性特征与单药已知特征相似。
  • 最高治疗剂量组客观缓解率为88%,总体人群总缓解率为83%。
  • 联合方案中AFM13半衰期最长可达20.6小时。

核心结论

  • AFM13联合帕博利珠单抗在重度经治R/R HL中总体耐受良好,安全性特征与两药单药已知特征相似。
  • 联合治疗在最高治疗剂量组客观缓解率为88%,总体人群总缓解率为83%。
  • 作者认为该概念验证研究提示这一新型免疫联合方案值得进一步研究。

研究设计与样本

  • 1b期剂量递增研究,评估AFM13联合帕博利珠单抗在复发或难治性霍奇金淋巴瘤患者中的安全性和初步疗效。
  • 主要目标为估计最大耐受剂量;次要目标为评估安全性、耐受性、抗肿瘤疗效、药代动力学和药效动力学。
  • 研究在www.clinicaltrials.gov注册,注册号为NCT02665650。

主要发现

  • 在重度经治患者人群中,AFM13联合帕博利珠单抗总体耐受良好,安全性特征与两药单药已知特征相似。
  • 最高治疗剂量组客观缓解率为88%,总体人群总缓解率为83%。
  • 联合方案中药代动力学评估显示AFM13半衰期最长可达20.6小时。

关键数值与推荐

  • 最高治疗剂量组客观缓解率为88%。
  • 总体人群总缓解率为83%。
  • 联合方案中AFM13半衰期最长可达20.6小时。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective was estimating the maximum tolerated dose; the secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pretreated patient population, treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020. PMID: 32730586. doi:10.1182/blood.2019004701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。